Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis

This trial showed that in patients with lymphangioleiomyomatosis (LAM), a progressive, cystic lung disease in women, sirolimus therapy was associated with stabilization of lung function, reduction in symptoms, and improvement in qualityof-life measures. Lymphangioleiomyomatosis (LAM) is an uncommon...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The New England journal of medicine Ročník 364; číslo 17; s. 1595 - 1606
Hlavní autori:	McCormack, Francis X, Inoue, Yoshikazu, Moss, Joel, Singer, Lianne G, Strange, Charlie, Nakata, Koh, Barker, Alan F, Chapman, Jeffrey T, Brantly, Mark L, Stocks, James M, Brown, Kevin K, Lynch, Joseph P, Goldberg, Hilary J, Young, Lisa R, Kinder, Brent W, Downey, Gregory P, Sullivan, Eugene J, Colby, Thomas V, McKay, Roy T, Cohen, Marsha M, Korbee, Leslie, Taveira-DaSilva, Angelo M, Lee, Hye-Seung, Krischer, Jeffrey P, Trapnell, Bruce C
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Massachusetts Medical Society 28.04.2011
Predmet:	Adult Double-Blind Method Female Forced Expiratory Volume - drug effects Human subjects Humans Intention to Treat Analysis Kinases Lungs Lymphangioleiomyomatosis - drug therapy Lymphangioleiomyomatosis - physiopathology Medication Adherence Middle Aged Observation Quality of Life Sirolimus - adverse effects Sirolimus - blood Sirolimus - therapeutic use TOR Serine-Threonine Kinases - antagonists & inhibitors Vascular endothelial growth factor Vital Capacity - drug effects Womens health
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!